You are here

  • Home
  • Archive
  • Volume 95, Issue 1
  • Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up

Article info

Article menu
Download PDFPDF
Clinical science
Original article
Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up

Authors

  1. Correspondence to Dr Alfredo Pece, Department of Ophthalmology, Melegnano Hospital, Via Pandina 1, 20077 Vizzolo Predabissi, Milan, Italy; pece.retina{at}mclink.it
View Full Text

Citation

Pece A, Isola V, Piermarocchi S, et al
Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up
British Journal of Ophthalmology 2011;95:56-68.

Publication history

  • Accepted March 6, 2010
  • First published July 3, 2010.
Online issue publication 
March 22, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.